European journal of endocrinology · 2026
Adverse health outcomes across the life course in individuals with six rare bone diseases: a 10-year population-based cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gaechter Pascal, Meier Christian, Christ Emanuel, Ebrahimi Fahim, Kutz Alexander, Szinnai Gabor
Аннотация
BACKGROUND: Rare bone diseases comprise a heterogeneous group of complex and disabling conditions. Evidence on age-specific hospitalization patterns and in-hospital outcomes across multiple rare bone diseases is limited.
METHODS: Population-based cohort study using national hospitalization data (01/2012-12/2021). Among 11 092 151 hospitalizations, 2875 admissions of children and adults with rare bone diseases were identified via ICD-10 codes (X-linked hypophosphatemia, osteogenesis imperfecta, fibrous dysplasia, achondroplasia, pseudohypoparathyroidism, fibrodysplasia ossificans progressiva) and compared with 14 375 age-, sex-, and patient complexity-matched hospitalizations from the general population.
RESULTS: Hospitalization patterns differed substantially by disease and age. Patients with X-linked hypophosphatemia had an increased risk of emergency admissions in late adulthood, whereas planned admissions were more frequent in early adulthood among patients with achondroplasia and fibrous dysplasia. Malignancies were diagnosed in 22.7% of patients with X-linked hypophosphatemia, and fractures were the leading cause of hospitalization among patients with osteogenesis imperfecta. Across the rare bone diseases, patients had higher all-cause in-hospital mortality compared with matched controls (RR, 2.26; 95% CI, 1.77-2.89), longer hospital stays (median difference, 6 days [interquartile range [IQR] 3-13 days]), higher risk of ICU admission (RR, 3.08; 95% CI, 2.78-3.40), and higher readmission risk (RR, 1.31, 95% CI, 1.15-1.49).
CONCLUSIONS: The studied rare bone diseases are associated with distinct, disease-specific hospitalization patterns and substantially worse in-hospital outcomes across the lifespan. This underscores the need for tailored preventive strategies and coordinated, long-term care models for patients with rare bone diseases.
METHODS: Population-based cohort study using national hospitalization data (01/2012-12/2021). Among 11 092 151 hospitalizations, 2875 admissions of children and adults with rare bone diseases were identified via ICD-10 codes (X-linked hypophosphatemia, osteogenesis imperfecta, fibrous dysplasia, achondroplasia, pseudohypoparathyroidism, fibrodysplasia ossificans progressiva) and compared with 14 375 age-, sex-, and patient complexity-matched hospitalizations from the general population.
RESULTS: Hospitalization patterns differed substantially by disease and age. Patients with X-linked hypophosphatemia had an increased risk of emergency admissions in late adulthood, whereas planned admissions were more frequent in early adulthood among patients with achondroplasia and fibrous dysplasia. Malignancies were diagnosed in 22.7% of patients with X-linked hypophosphatemia, and fractures were the leading cause of hospitalization among patients with osteogenesis imperfecta. Across the rare bone diseases, patients had higher all-cause in-hospital mortality compared with matched controls (RR, 2.26; 95% CI, 1.77-2.89), longer hospital stays (median difference, 6 days [interquartile range [IQR] 3-13 days]), higher risk of ICU admission (RR, 3.08; 95% CI, 2.78-3.40), and higher readmission risk (RR, 1.31, 95% CI, 1.15-1.49).
CONCLUSIONS: The studied rare bone diseases are associated with distinct, disease-specific hospitalization patterns and substantially worse in-hospital outcomes across the lifespan. This underscores the need for tailored preventive strategies and coordinated, long-term care models for patients with rare bone diseases.